The Phase I clinical trial (PROCEADE-CRC-01) has brought new hope to patients with advanced CRC: the global first anti-CEACAM5 antibody-drug conjugate (ADC) Precem-TcT has demonstrated significant safety and encouraging efficacy in heavily pretreated metastatic colorectal cancer patients27. The gene discussed is CEACAM5; the disease is colorectal carcinoma.